Clearance of hepatitis c virus after fixed-dose combination ledipasvir/sofosbuvir in an adolescent female with decompensated cirrhosis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 63, Issue 5, 2016, Pages 516-517

  Smith, Sara K ^a   Rosenthal, Philip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cirrhosis; Direct acting antivirals; Hepatitis C virus; Ledipasvir sofosbuvir; Liver transplant; Pediatrics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; HEPATITIS C ANTIBODY; LEDIPASVIR PLUS SOFOSBUVIR; VITAMIN K GROUP; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CAUCASIAN; CHRONIC HEPATITIS C; COMPASSIONATE USE; CYTOPENIA; DECOMPENSATED LIVER CIRRHOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; EMERGENCY WARD; EPISTAXIS; ESOPHAGOSCOPY; ESOPHAGUS VARICES; FEMALE; FEVER; FIBRINOGEN DEFECT; FLANK PAIN; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAOPERATIVE PERIOD; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER NODULE; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; NEUTROPENIA; PANCYTOPENIA; PATIENT REFERRAL; PEDIATRIC SURGERY; PRIORITY JOURNAL; SEPSIS; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERTICAL TRANSMISSION; VIRAL CLEARANCE; VIRUS LOAD; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS;

ADOLESCENT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; SOFOSBUVIR; VIRAL LOAD;

EID: 84973124299     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001278     Document Type: Article

References (6)

1. Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr 2016;28:93-100.
2. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012;18:99-104.
3. Simmons B, Saleem J, Heath K, et al. Long term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 2015;61:730-40.
4. Kirby B. Adult doses of sofosbuvir plus ribavirin or ledipasvir/sofosbuvir provided comparable plasma exposures and tolerable safety profile in adolescents with hepatitis C virus (HCV) infection. Presented at: American Association for the Study of Liver Disease Annual Meeting; 2015; San Francisco, CA.
5. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-59.
6. Gane EJ, Hyland RH, An D, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult to treat populations including genotype 3 patients, decompensated type 3 patients and genotype 1 patients with prior sofosbuvir treatment experience. J Hepatol 2014; 60:S3-4.